Sign In
Buy MRSN
$29.08
+0 (+0%)
At Close: Apr 02, 2026
Mersana Therapeutics to Present at the Cowen 42nd Annual Health Care Conference
08:00am, Wednesday, 02'nd Mar 2022
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates
12:15pm, Monday, 28'th Feb 2022 Zacks Investment Research
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -1.49% and 10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st
Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q4 2021 Results - Earnings Call Transcript
11:25am, Monday, 28'th Feb 2022
Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q4 2021 Results - Earnings Call Transcript
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates
08:28am, Monday, 28'th Feb 2022
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -1.49% and 10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st
Cytokinetics (CYTK) Reports Q4 Loss, Tops Revenue Estimates
10:20pm, Thursday, 24'th Feb 2022 Zacks Investment Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of 59.55% and 931.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Mersana Therapeutics (MRSN) This Earnings Season?
10:50am, Thursday, 24'th Feb 2022
Mersana Therapeutics (MRSN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Analysts Estimate Mersana Therapeutics, Inc. (MRSN) to Report a Decline in Earnings: What to Look Out for
10:07pm, Friday, 18'th Feb 2022 Zacks Investment Research
Mersana Therapeutics, Inc. (MRSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Mersana Therapeutics, Inc. (MRSN) to Report a Decline in Earnings: What to Look Out for
06:34pm, Friday, 18'th Feb 2022
Mersana Therapeutics, Inc. (MRSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
01:31pm, Wednesday, 09'th Feb 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Humanigen Announces Agreement With French CDMO For Fill And Finish Services For Lenzilumab
Humanigen,
Janssen Inks Over $1B Pact For Mersana's ADC Technology In Three targets
01:39pm, Thursday, 03'rd Feb 2022
Mersana Therapeutics Inc MRSN has announced a research collaboration and license agreement with Janssen Biotech Inc, a unit of Johnson & Johnson JNJ, to discover antibody-drug conjugates (ADCs)
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
01:13pm, Thursday, 03'rd Feb 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Syros' Blood Cancer Drugs Land Orphan Designation From FDA
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS)
Mersana Therapeutics Announces 2022 Strategic Priorities and Milestones
01:00pm, Friday, 07'th Jan 2022 GlobeNewswire Inc.
UPLIFT, a single-arm registrational trial of UpRi in platinum-resistant ovarian cancer, expected to complete enrollment in Q3 2022
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets
01:20pm, Wednesday, 05'th Jan 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial
Annexon, Inc. (NASDAQ: ANNX) announ
Mersana Therapeutics to Participate in the Upcoming 4th Annual Evercore ISI HealthCONx Conference
01:00pm, Tuesday, 23'rd Nov 2021 GlobeNewswire Inc.
CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-
Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q3 2021 Results - Earnings Call Transcript
01:10pm, Tuesday, 09'th Nov 2021
Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q3 2021 Results - Earnings Call Transcript
